Apollon Wealth Management LLC Purchases 6,474 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Apollon Wealth Management LLC lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 62.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,854 shares of the medical equipment provider's stock after purchasing an additional 6,474 shares during the period. Apollon Wealth Management LLC's holdings in Intuitive Surgical were worth $8,347,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ISRG. AlphaCore Capital LLC increased its holdings in shares of Intuitive Surgical by 4.2% in the 4th quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock valued at $235,000 after acquiring an additional 18 shares during the last quarter. Accredited Investors Inc. lifted its stake in Intuitive Surgical by 1.9% during the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock worth $543,000 after purchasing an additional 19 shares during the last quarter. Second Line Capital LLC increased its stake in Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after purchasing an additional 19 shares during the last quarter. Colonial Trust Co SC raised its holdings in shares of Intuitive Surgical by 8.8% during the fourth quarter. Colonial Trust Co SC now owns 246 shares of the medical equipment provider's stock worth $128,000 after purchasing an additional 20 shares during the period. Finally, Crown Wealth Group LLC raised its holdings in shares of Intuitive Surgical by 4.8% during the first quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock worth $218,000 after purchasing an additional 20 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Intuitive Surgical Stock Up 0.1%

Shares of NASDAQ ISRG traded up $0.41 during mid-day trading on Wednesday, hitting $512.64. 1,850,129 shares of the company traded hands, compared to its average volume of 1,684,751. The business has a 50 day moving average of $537.18 and a two-hundred day moving average of $536.37. The stock has a market capitalization of $183.74 billion, a price-to-earnings ratio of 75.17, a PEG ratio of 5.48 and a beta of 1.64. Intuitive Surgical, Inc. has a 1 year low of $413.82 and a 1 year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. The company had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. During the same period last year, the company posted $1.50 earnings per share. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Activity

In related news, Director Jami K. Nachtsheim sold 2,400 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the completion of the sale, the director directly owned 6,371 shares in the company, valued at approximately $3,312,920. This trade represents a 27.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 188 shares of the company's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $515.91, for a total transaction of $96,991.08. Following the completion of the transaction, the executive vice president owned 5,224 shares in the company, valued at approximately $2,695,113.84. This represents a 3.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,998 shares of company stock valued at $2,611,577 in the last 90 days. Company insiders own 0.70% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Citigroup reaffirmed a "buy" rating and set a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Evercore ISI increased their price target on Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Robert W. Baird reduced their price objective on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Truist Financial lowered their price objective on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft lowered Intuitive Surgical from a "hold" rating to a "sell" rating and dropped their target price for the stock from $515.00 to $440.00 in a research report on Monday, June 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $592.86.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.